[1] [1] Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy[J]. Nat Rev Clin Oncol, 2023, 20(12): 864-884.

[2] [2] Toh MR, Wong EYT, Wong SH, et al. Global epidemiology and genetics of hepatocellular carcinoma[J]. Gastroenterology, 2023, 164(5): 766-782.

[3] [3] Cao L, Liu M, Ma X, et al. Comprehensive scRNA-seq analysis and identification of CD8+ T cell related gene markers for predicting prognosis and drug resistance of hepatocellular carcinoma[J]. Curr Med Chem, 2024, 31(17): 2414-2430.

[6] [6] Lei Y, Han P, Chen Y, et al. Protein arginine methyltransferase 3 promotes glycolysis and hepatocellular carcinoma growth by enhancing arginine methylation of lactate dehydrogenase A[J]. Clin Transl Med, 2022, 12(1): e686.

[11] [11] Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77(6): 1598-1606.

[12] [12] Liao Z, Tang C, Luo R, et al. Current concepts of precancerous lesions of hepatocellular carcinoma: recent progress in diagnosis[J]. Diagnostics (Basel), 2023, 13(7): 1211.

[14] [14] Lin Z, Huang Z, Qiu J, et al. m6A-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2024, 43(1): 206.